HPM Partners LLC bought a new position in shares of Cantel Medical Corp. (NYSE:CMD) in the second quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm bought 3,106 shares of the company’s stock, valued at approximately $252,000.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. Connable Office Inc. acquired a new position in Cantel Medical Corp. in the second quarter valued at about $256,000. Pennsylvania Trust Co acquired a new position in Cantel Medical Corp. in the second quarter valued at about $6,590,000. Rhumbline Advisers acquired a new position in Cantel Medical Corp. in the second quarter valued at about $5,892,000. Capstone Asset Management Co. acquired a new position in Cantel Medical Corp. in the second quarter valued at about $690,000. Finally, Russell Investments Group Ltd. acquired a new position in Cantel Medical Corp. in the second quarter valued at about $1,714,000. 84.28% of the stock is owned by institutional investors.

A number of research firms recently commented on CMD. Sidoti raised Cantel Medical Corp. from a “neutral” rating to a “buy” rating and set a $92.00 price target for the company in a research note on Wednesday, August 2nd. Zacks Investment Research raised Cantel Medical Corp. from a “hold” rating to a “buy” rating and set a $83.00 price target for the company in a research note on Tuesday, August 1st. Benchmark Co. downgraded Cantel Medical Corp. from a “buy” rating to a “hold” rating in a research note on Friday, June 9th. Finally, Needham & Company LLC reaffirmed a “hold” rating on shares of Cantel Medical Corp. in a research note on Thursday, June 8th. Four research analysts have rated the stock with a hold rating and one has issued a buy rating to the stock. The stock has a consensus rating of “Hold” and a consensus target price of $91.67.

Cantel Medical Corp. (CMD) opened at 82.68 on Tuesday. Cantel Medical Corp. has a 1-year low of $68.19 and a 1-year high of $88.81. The firm has a market cap of $3.43 billion, a P/E ratio of 48.92 and a beta of 1.23. The company has a 50-day moving average price of $76.82 and a 200-day moving average price of $76.53.

In other Cantel Medical Corp. news, Chairman Charles M. Diker sold 35,000 shares of the firm’s stock in a transaction dated Wednesday, July 12th. The stock was sold at an average price of $75.52, for a total value of $2,643,200.00. Following the completion of the transaction, the chairman now owns 3,114,520 shares in the company, valued at approximately $235,208,550.40. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. 14.90% of the stock is owned by company insiders.

WARNING: This report was published by The Cerbat Gem and is owned by of The Cerbat Gem. If you are reading this report on another domain, it was illegally copied and reposted in violation of U.S. and international copyright and trademark law. The legal version of this report can be read at https://www.thecerbatgem.com/2017/09/12/3106-shares-in-cantel-medical-corp-cmd-purchased-by-hpm-partners-llc.html.

Cantel Medical Corp. Profile

Cantel Medical Corp. is a provider of infection prevention products and services in the healthcare market. The Company’s operating segments include Endoscopy; Water Purification and Filtration; Healthcare Disposables, and Dialysis. Its Endoscopy segment includes medical device reprocessing systems, disinfectants, detergents and other supplies.

Institutional Ownership by Quarter for Cantel Medical Corp. (NYSE:CMD)

Receive News & Stock Ratings for Cantel Medical Corp. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cantel Medical Corp. and related stocks with our FREE daily email newsletter.